Replies to post #2656 on Entremed (ENMD)

[vk707]

Actually, some pertinent posts on the internet may have played a role for those assigned the task of disposing of, shall we say , excess income. You just never know when some tintilatin' tidbit of research trivia throws the balance.

But fer you youngsters 'ol vk has some SAGE advice if in ya wanna git rid of yur fortune. ALL ya have to do is.....

V
V
V
V
V
GET YUR SELF MARRIED

V
V
V
V
V
V
V

A LOT.....


Best to alll,
vk 'n Fargo

[docaaron1]

Cycle dude, note the reference to HIF-1a inhibiting drugs in the Komen grant press release. Someone also posted on the Yahoo board that other companies are working on HIF-1a inhibitors. Imitation is the sincerest form of flattery and we have a head start in human patients. The NCD formula has been used in humans since the beginning of the year. I don't believe Panzem NCD will have the side effects of YC-1 but we won't know until the results are made public. I don't believe they would be trying Panzem NCD with docetaxel in human subjects if the NCD trials were having problems. Let's hope that Panzem NCD takes off and leaves the competition in the dust.

Aaron


From the press release:
http://biz.yahoo.com/prnews/050629/dcw006.html?.v=17

"...Through studies performed under this grant, we hope to determine which chemotherapy agents and HIF- 1alpha inhibiting drugs work best together."


From a YC-1 study:
http://www.signaling-gateway.org/update/updates/200305/nrc1087.html

"...So, it seems from this initial study that YC-1 could be used to 'suffocate' many types of tumour by preventing their ability to cope with hypoxia. Its low toxicity in the mouse study is an important advantage, although owing to its other known actions in the circulation, possible side effects in humans include increased bleeding time and hypotension."